Compare ACADIA Pharmaceuticals Inc. (ACAD) vs JPMorgan Ultra Short Income ETF (JPST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs JPMorgan Ultra Short Income ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while JPMorgan Ultra Short Income ETF trades at $50.44. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | JPST | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $28.06 | $50.78 |
52-Week Low | $20.06 | $50.40 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
JPST, the JPMorgan Ultra-Short Income ETF, trades at $50.45, up 0.06% on the day. The technical outlook is bearish based on moving averages, with oscillators neutral. Recent news highlights its role as a cash alternative, with institutional inflows and consistent monthly dividends. The fund focuses on high-quality, short-term bonds for income and capital preservation.
The outlook remains stable given its low-risk profile, offering a yield advantage over savings accounts. Risks include interest rate sensitivity and credit spread changes. Wall Street sentiment is positive for risk-averse investors seeking short-term income, though technical indicators suggest near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →
